Dr Marlies Wijsenbeek
Dr Marlies Wijsenbeek Centre of Interstitial Lung Diseases, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands Marlies Wijsenbeek is a pulmonary physician at the Erasmus MC [...]
Dr Marlies Wijsenbeek Centre of Interstitial Lung Diseases, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands Marlies Wijsenbeek is a pulmonary physician at the Erasmus MC [...]
Professor Toby Maher Toby Maher is Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles. He has spent the [...]
Professor Kevin R. Flaherty Dr. Kevin R. Flaherty is a Professor of Medicine in the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine at the University of Michigan [...]
Professor Surinder Birring Surinder Birring is Professor of Respiratory Medicine and Consultant Respiratory Physician at King’s College Hospital, London (specialist clinics in ILD, Cough [...]
Professor Michael Tharp, MD Michael D. Tharp, MD is Clark W. Finnerud, M.D. Professor and Chair of the Department of Dermatology at Rush University Medical Center. Dr. Tharp graduated cum laude [...]
Martin Metz Martin Metz is Professor of Dermatology with focus on pruritus research at the Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Germany. He received his [...]
Sonja Ständer, MD Sonja Ständer is professor for Dermatology and Neurodermatology at the Department of Dermatology, and head of the Interdisciplinary Competence Center Chronic Pruritus (KCP) of [...]
Dr Mandel Sher Dr. Mandel Sher is a Professor of Medicine and Pediatrics at the University of South Florida, Division of Allergy & Immunology. As USF faculty at Johns Hopkins All Children’s [...]
Professor Alyn H Morice Professor Morice qualified at Cambridge University and after House jobs in London undertook research (MD) into the pharmacology of asthma at St Mary’s Hospital. As [...]
NeRRe Therapeutics is a UK based clinical-stage company developing a unique portfolio of neurokinin (NK) receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity.